Arthneeti

Alkem Laboratories Q1 FY27 Share Price & Earnings Call Analysis

₹5,079.00+0.18% today
Market cap
₹60,727 Cr
P/E
26.73
ROE
18.89%
PEG
0.84
Price to sales
4.03
Debt to equity
0.15
52W high / low
₹5,890 / ₹4,947
Sales growth (5Y)
10.66%
EBITDA margin
20.11%
Net profit margin
16.92%
Promoter holding
49.70%
Sales (last year)
₹15,081 Cr

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Guidance scorecard · Q1 FY27 call

What Alkem Laboratories Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#60of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingNone plannedOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • International Business: Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. U.S. business remains flat to high single-digit growth due to pricing pressure and currency effects.
  • U.S. Market: Anticipated growth in high single to mid-single digits in FY27, helped by currency benefits. No major volume expansion seen in last 12-24 months.
  • India Business: Branded formulations expected to grow around 12%; Trade Generics growth slower—late single digits anticipated with disciplined execution.

2 more points from Alkem Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Alkem Laboratories Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • The company currently has reasonable capacity at its CDMO facility in the U.S., with some specialized technology; however, it is relatively small.
  • Future capex will be required at the CDMO facility to ramp up production and achieve economies of scale, but this is not expected to happen in the current fiscal year.
  • No plans for acquisitions in the orthopedics or MedTech segment at present; focus is on ramping up existing operations.
  • Overall, capex related to CDMO expansion is planned but timed based on business growth and scale requirements.
Full Q1 FY27 analysis

FundraisingQ1 FY27 call

None planned

See what Alkem Laboratories Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • The management mentioned they would provide this information later.
  • For the U.S. CDMO (Contract Development and Manufacturing Organization) business, the revenue breakeven is expected at an annualized USD 25-30 million run rate.
  • The CDMO business has a decent project pipeline but the sales cycle is long and lumpy, dependent on client funding and clinical trial progress.
  • The company anticipates CDMO revenues to start rising in FY27 and FY28, with the USD 30 million revenue target expected by FY28.

2 more points from Alkem Laboratories Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Alkem Laboratories Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Alkem Laboratories Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Alkem Laboratories Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Alkem Laboratories Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +2,9032,9683,4403,3242,9363,0323,4153,3743,1443,3714,0013,7373,603
Expenses +2,5492,5792,6932,6162,5342,4232,6622,6152,7522,6323,0802,9093,086
Operating Profit353389747708402609753759391739921828517
OPM %12%13%22%21%14%20%22%23%12%22%23%22%14%
Other Income +-346664276120134931461491049065
Interest29303025272928362830354254
Depreciation7872747083807985112889495106
Profit before tax212353648655367619780731396771896781423
Tax %68%18%5%8%17%11%10%12%18%13%13%16%40%
Net Profit +68288615604304550702641322668779653251
EPS in Rs5.9423.9851.9049.7624.5545.6057.6052.3425.5855.5663.9953.1919.78

Financials of Alkem Laboratories Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +3,6744,9055,6886,4017,3578,3448,86510,63411,59912,66812,96514,712
Expenses +3,2484,0384,6875,3926,2376,8686,9208,5809,97710,41910,45211,707
Operating Profit4278661,0011,0091,1201,4761,9452,0541,6222,2492,5123,005
OPM %12%18%18%16%15%18%22%19%14%18%19%20%
Other Income +17622711011582102230146101186494409
Interest8171455555655952107112122161
Depreciation7193101143193253275304310299357382
Profit before tax4519289659269551,2601,8421,8441,3052,0232,5272,871
Tax %13%19%6%31%19%9%12%9%23%10%12%18%
Net Profit +3927529056387741,1491,6181,6801,0071,8112,2152,351
EPS in Rs32.7562.0274.6152.7763.6194.26132.57137.6382.31150.19181.11192.51
Dividend Payout %12%20%20%25%25%27%23%25%61%27%25%28%

Financials of Alkem Laboratories Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital242424242424242424242424
Reserves2,9753,6684,4444,8405,4156,1377,3538,6149,02110,28811,96113,796
Borrowings +1,3066586599989441,6161,7072,6681,3971,4181,3812,047
Other Liabilities +9861,1841,4401,8031,8242,1692,4352,7633,3153,8444,3255,006
Total Liabilities5,2915,5346,5687,6648,2089,94611,51914,06913,75715,57517,69120,873
Fixed Assets +1,3741,4501,7972,2842,5302,9082,7932,9022,6832,8732,8524,015
CWIP111172299381493363393339323159548138
Investments4815095534443242613333716224841,8461,869
Other Assets +3,3253,4033,9184,5554,8616,4138,00010,45710,12912,06012,44514,851
Total Assets5,2915,5346,5687,6648,2089,94611,51914,06913,75715,57517,69120,873

Financials of Alkem Laboratories Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +3257264712667805851,2651,1111,6821,9481,913
Cash from Investing Activity +-235205-294-351-318-737-995-1,433120-1,011-1,288
Cash from Financing Activity +-52-927-13885-37979-272380-1,761-1,145-811
Net Cash Flow39340082-73-25842-207-186
Free Cash Flow190472-163-4112532371,1167831,4531,7611,278
CFO/OP101%107%73%47%92%59%86%73%121%105%96%

Financials of Alkem Laboratories Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days524246626272666567656974
Inventory Days169169198221186198241262194197224239
Days Payable10110812214711910411210287129141161
Cash Conversion Cycle121103122135129167196225174132152152
Working Capital Days-521334405544483166135124141
ROCE %12%23%21%17%16%18%22%18%14%20%20%21%

Guidance history

How Alkem Laboratories Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlannedNone planned—
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlannedPlanned—
Q2 FY26 call →10–20%Up 0–2%Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

22out of 100

Momentum score · price trend

22 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−8.2%51%
Last 6 months−5.9%43%
Last 3 months−12.7%34%

The price is 20.2% below its all-time high of ₹6,366.25 (13 Sept 2024). Stocks more than 20% below their peak have their score halved, so 44 became 22.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Alkem Laboratories Ltd: 0.4 × 51 + 0.4 × 43 + 0.2 × 34 = 44, halved to 22 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Alkem Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd